Deals
Ipsen to Step Up Deal-Making, Scout for New Cancer Products
- CEO De Garidel mined JPMorgan conference for opportunities
- Two, three transactions worth up to EU300 million most likely
This article is for subscribers only.
Ipsen SA Chief Executive Officer Marc de Garidel says the French drugmaker needs to clinch more deals to beef up its stable of products in areas such as digestive cancers -- and he tapped an industry conference last week to mingle with potential partners.
The company, based in Boulogne-Billancourt near Paris, has 200 million euros ($217 million) in cash and could easily raise an additional 600 million euros for potential transactions, de Garidel said in an interview last Thursday at the JPMorgan Chase & Co. health conference in San Francisco.